# Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant

Study · id `cardio:ct-nct02988115` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02988115](<https://clinicaltrials.gov/study/NCT02988115>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02988115

Browse, organ or system: Blood vessels; Metabolism  
Browse, condition area: Risk and prevention; Coronary and vascular disease; Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 345 participants.

## Technical summary

Registry record NCT02988115. Randomized; triple masking; primary purpose treatment. Start 2016-11-16 (actual); primary completion 2018-03-16 (actual). Results posted on 2020-04-03.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 345 participants (enrolled count; ClinicalTrials.gov record NCT02988115, source copy `cardio:ctgov-nct02988115-2020-04-03`, retrieved 2026-10-31)
- Started: 2016-11-16 (actual) (ClinicalTrials.gov record NCT02988115, source copy `cardio:ctgov-nct02988115-2020-04-03`, retrieved 2026-10-31)
- Primary completion: 2018-03-16 (actual) (ClinicalTrials.gov record NCT02988115, source copy `cardio:ctgov-nct02988115-2020-04-03`, retrieved 2026-10-31)
- Completion: 2018-03-16 (actual) (ClinicalTrials.gov record NCT02988115, source copy `cardio:ctgov-nct02988115-2020-04-03`, retrieved 2026-10-31)
- Results first posted: 2020-04-03 (ClinicalTrials.gov record NCT02988115, source copy `cardio:ctgov-nct02988115-2020-04-03`, retrieved 2026-10-31)
- Countries: United States; Canada (ClinicalTrials.gov record NCT02988115, source copy `cardio:ctgov-nct02988115-2020-04-03`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02988115-2020-04-03`, retrieved 2026-10-31)

## The registry's words

- Brief title: Evaluation of the Efficacy and Safety of Bempedoic Acid (ETC-1002) in Patients With Hyperlipidemia and Statin Intolerant
- Acronym: CLEAR Serenity
- Condition: Hypercholesterolemia
- Condition: Atherosclerotic Cardiovascular Disease
- Condition: Statin Adverse Reaction
- Intervention (Drug): bempedoic acid
- Intervention (Other): placebo
- Lead sponsor: Esperion Therapeutics, Inc.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Atherosclerosis (`cardio:atherosclerosis`)
- Registry condition terms include this condition: Dyslipidemia (`cardio:dyslipidemia`)
- Registry condition terms include this condition: High cholesterol (hypercholesterolemia) (`cardio:hypercholesterolemia`)
- Registry intervention name matches this record: Bempedoic acid (`cardio:bempedoic-acid`)
- Registry lists this organization as the lead sponsor: Esperion Therapeutics, Inc. (`cardio:org-esperion-therapeutics-inc`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Efficacy and Safety of Bempedoic Acid in Patients With Hypercholesterolemia and Statin Intolerance (`cardio:pubmed-30922146`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: b9c09a686c35728347256f62502993edb6d1ff2a2732ccd7d34db6b58d674f85
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
